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Integrated genomic approaches 
identify major pathways and 
upstream regulators in late onset 
Alzheimer’s disease
Xinzhong Li1, Jintao Long1, Taigang He2, Robert Belshaw3, & James Scott4
Previous studies have evaluated gene expression in Alzheimer’s disease (AD) brains to identify 
mechanistic processes, but have been limited by the size of the datasets studied. Here we have 
implemented a novel meta-analysis approach to identify differentially expressed genes (DEGs) in 
published datasets comprising 450 late onset AD (LOAD) brains and 212 controls. We found 3124 
DEGs, many of which were highly correlated with Braak stage and cerebral atrophy. Pathway 
Analysis revealed the most perturbed pathways to be (a) nitric oxide and reactive oxygen species in 
macrophages (NOROS), (b) NFkB and (c) mitochondrial dysfunction. NOROS was also up-regulated, 
and mitochondrial dysfunction down-regulated, in healthy ageing subjects. Upstream regulator 
analysis predicted the TLR4 ligands, STAT3 and NFKBIA, for activated pathways and RICTOR for 
mitochondrial genes. Protein-protein interaction network analysis emphasised the role of NFKB; 
identified a key interaction of CLU with complement; and linked TYROBP, TREM2 and DOK3 to 
modulation of LPS signalling through TLR4 and to phosphatidylinositol metabolism. We suggest 
that NEUROD6, ZCCHC17, PPEF1 and MANBAL are potentially implicated in LOAD, with predicted 
links to calcium signalling and protein mannosylation. Our study demonstrates a highly injurious 
combination of TLR4-mediated NFKB signalling, NOROS inflammatory pathway activation, and 
mitochondrial dysfunction in LOAD.
Alzheimer’s disease (AD) is a devastating dementia affecting 5–10% of people over 65 years, and 30% 
of people older than 85 years. AD accounts for around 60 percent of dementia and affects 44 million 
people globally, 5.2 million in the USA and 850,000 in the UK. In the absence of effective treatments, 
these numbers are estimated to increase by up to 50% by 2025 both in the USA and UK (http://www.
alzheimers.org.uk/)1,2.
AD develops slowly over many years with the accumulation of characteristic senile (amyloid) plaques 
and neurofibrillary tangles (NFT) accompanied by neuroinflammation. Ultimately there is a loss of brain 
cells and synaptic connections as symptoms develop. Certain mutations in APP, PSEN1 and PSEN2 
inevitably lead to early-onset AD (EOAD) at around the age of 50 years in five percent of sufferers. 
Approximately 50% of the risk of late onset AD (LOAD) can be explained by genetic factors. The apo-
lipoprotein E variant, APOE4, found in 15% of the population, is the major genetic risk factor for 
LOAD. APOE4 contributes around six percent to the phenotypic variance in AD, and it is estimated that 
between 40% and 65% of people diagnosed with AD have one or two copies of the variant APOE4 gene1. 
Genome-wide association studies (GWAS) coupled with meta-analysis have identified 21 AD genes with 
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low odds ratios, along with more genes at borderline statistical significance for GWAS3. The other half of 
LOAD risk is conferred by modifiable risk factors, which are mostly also risk factors for cardiovascular 
disease including atherosclerosis, high blood cholesterol, high blood pressure, midlife obesity, diabetes, 
smoking, physical inactivity and Western diet (http://www.alz.org). While the genetic and modifiable AD 
risk factors are linked by related mechanisms involving inflammation, cerebral blood flow, lipid metab-
olism and cell membrane processes4, there is a substantial gap in our understanding of the mechanisms 
underlying AD pathogenesis.
Meta-analysis combines the results of different independent studies, and allows the discovery of pat-
terns of association due to the increased statistical power of larger combined sample sizes. It is widely 
used in clinical systematic review5, genome wide association studies (GWAS)3,6 and microarray stud-
ies7,8. The use of public databases, meta-analysis and data integration have been extraordinarily valuable 
especially in investigating complex diseases such as AD. For example, two studies recently identified 
TYROBP, which modulates TLR4 signalling in brain microglia, as a potential causal regulator in LOAD, 
and other studies have identified REST as a major modulator in LOAD or discovered multiple genes 
interacting mechanistically with APOE49–12.
Here we used a novel statistical approach to meta-analysis of microarray gene expression datasets to 
discover differentially expressed genes (DEGs) in AD. The main feature of our approach is that it avoids 
relying solely on those genes for which there are expression data from each constituent study (we call 
these the common genes). Our study constitutes the largest dataset so far analysed, comprising 450 
cases and 212 controls. We also performed pathway and upstream regulator analyses using QIAGEN’s 
Ingenuity® Pathway Analysis (IPA® , QIAGEN Redwood City, www.qiagen.com/ingenuity) tools, and 
protein-protein interaction (PPI) network analysis. Our analyses revealed novel genes with potential 
involvement in AD, and pathways highly perturbed in AD.
Results
Differentially expressed genes from meta-analysis. Meta-analysis was conducted on six previ-
ous gene expression studies comprising 450 AD and 212 healthy human brain tissue samples from the 
frontal cortex, including 23530 unique genes shown in Supplementary Table S1 online. After Bonferroni 
correction (metaPval < 0.05/23530), 3124 differentially expressed genes (DEGs) were identified (1358 
up-regulated and 1766 down-regulated). Only 3838 of the 23530 genes (16.3%) were found in all six 
studies (the common genes) and only 918 (23.9%) of these common genes were identified as DEGs. Our 
total of 3124 DEGs also include 1582 (50.6%) genes that were found in five studies; 242 (7.7%) in four; 
213 (6.8%) in three and 169 (5.4%) in two studies. Clearly, had we only analysed the common genes, 
we would have missed most of the DEGs (the entire list of 3124 DEGS can be found in Supplementary 
Table S2 online). We present here the results of an effect size approach in the meta-analysis; an alternate 
p-value based meta-analysis approach with Bonferroni correction gave very similar results: it identified 
3315 DEGs with 3123 overlapping between these two approaches (representing 99.9% and 94.2% of the 
DEGs identified separately).
We found 2586 out of the 23530 genes were significantly correlated with Braak pathological stage or 
frontal atrophy in AD patients using data in Zhang et al. study11, and 1612 of these were identified as 
DEGs. This demonstrated a high ratio of enrichment (OR = 21.26, 95%CI 19.32 ~ 23.42, p-value < 2.2E-
16, Fisher-test). We also observed a high ratio of enrichment in DEGs between gene expression and 
frontal lobe atrophy (OR = 16.29, 95%CI 14.94 ~ 17.78, p-value < 2.2E-16). Overall, DEGs have 3.39% 
(p-value < 2.2E-16, t-test) and 5.54% (p-value < 2.2E-16, t-test) increased correlations compared to 
non-DEGs with Braak stage and frontal atrophy respectively (Supplementary Fig. S1 online). There are 
twenty top modules identified in gene co-expression regulatory network in AD in the Zhang et al. study, 
half of which are enriched with DEGs identified in this study (Supplementary Table S3 online), including 
immune and microglia (OR = 6.49, p-value = 4.93E-146, Fisher-test); synaptic transmission and neurons 
(OR = 3.5, p-value = 8.89E-43); coated vesicle (OR = 4.41, p-value = 4.41E-23); and unfolded protein 
(OR = 2.29, p-value = 2.06E-15).
The top 30 DEGs identified in this study are shown in Table 1, which includes 12 up-regulated and 
18 down-regulated genes. Only 17 of the 30 genes (56.7%) were reported from all six studies and 13 
(43.3%) were missed in one study. For all of these 30 DEGs, there is a strong correlation between gene 
expression and Braak pathological stage or frontal atrophy in AD patients. Overall the up/down effects 
and positive/negative correlations agree strongly with each other, and are indicative of strong associa-
tion with AD pathology for each gene. Six of the top seven DEGs are highly correlated with Braak stage 
(absolute r > 0.7) and are down-regulated, namely NEUROD6, ZCCHC17, PPEF1, MANBAL, BDNF 
and CRH. We highlight among the top 30 DEGs the following genes: C1QA, DOK3 and NFKBIB, and 
MS4A6A. DOK3 docks with TYROBP, a microglial regulator in AD, and with TREM2, which has been 
linked to AD by GWAS. Together these two proteins limit bacterial lipopolysaccaride (LPS) signalling 
through TLR411,13,14. NFKBIA is a major pro-inflammatory transcription factor (TF) downstream of 
TLR4. C1QA is a major complement component and is regulated by NFKB in macrophages15. MS4A6A 
is the only GWAS-discovered AD gene amongst the top 30. In microglia, its expression co-varies 
with that of TYROBP11. The expression of these top DEGs varies across different brain regions in AD 
(Supplementary Method and Table S4 online). For example ZCCHC17 was consistently down-regulated 
in four brain regions including the hippocampus, while NEUROD6 was down-regulated only in medial 
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temporal gyrus and superior frontal gyrus; and MS4A6A was not a DEG in any of these six regions in 
that particular dataset.
The most recent large GWAS meta-analysis of AD cases and controls3 identified 21 AD risk genes. 
Further studies identified two additional AD loci, TRIP416 and PLD317. These 23 genes were included in 
our initial 23530 gene pool. Seven of them were identified as DEGs with at least two-fold enrichment 
compared to non-GWAS genes (OR = 2.86, 95%CI 0.99 ~ 7.36, p-value = 2.56E-2, Fisher-test) indicating 
that genes detected by GWAS are more likely to be DEGs in AD (Supplementary Table S5 online). The 
non-DEGs found in GWAS were either missed in too many studies (e.g. TXNDC3) or were inconsistent 
in their direction of regulation across the studies (e.g. BIN1). Expression of the top five differentially 
expressed genes found by GWAS - MS4A6A, CD2AP, INPP5D, MEF2C and CLU – all have good corre-
lation with Braak stage and cerebral atrophy.
Pathway analysis. We applied QIAGEN’s Ingenuity® Pathway Analysis (IPA® , QIAGEN Redwood 
City, www.qiagen.com/ingenuity) tool to our DEGs, analysing the up- and down-regulated DEGs sep-
arately. For the 1322 up-regulated DEGs mapped to IPA (genes not mapped to the IPA database were 
excluded in our pathway analysis), 165 significant canonical pathways were identified (BH adjusted 
p-value < 0.01, see Supplementary Table S6 online). These include Production of the Nitric Oxide 
and Reactive Oxygen Species in Macrophages pathway (NOROS, adjPval = 1.26E-12, ratio = 44/180); 
NFKB Signalling (adjPval = 1.26E-11, ratio = 41/173); the Role of Macrophages, Fibroblasts and 
Table 1. The top 30 most significant DEGs
EntrezGene Symbol metaZscore metaPval avgFC$ Effect# adjPval Braak* Atrophy*
63974 NEUROD6 − 9.93 0 0.60 − − − − − − 0 − 0.77 − 0.62
51538 ZCCHC17 − 8.91 0 0.81 − − − − − − 0 − 0.73 − 0.59
5475 PPEF1 − 8.9 0 0.61 − − − − − − 0 − 0.76 − 0.61
712 C1QA 8.76 0 1.59 ?+ + + + + 0 0.61 0.47
63905 MANBAL − 8.76 0 0.87 − − ?− − − 0 − 0.73 − 0.58
627 BDNF − 8.74 0 0.61 − − ?− − − 0 − 0.76 − 0.58
1392 CRH − 8.73 0 0.54 − − ?− − − 0 − 0.77 − 0.58
3707 ITPKB 8.68 0 1.80 + + + + + + 0 0.75 0.57
388341 FAM211A − 8.68 0 0.84 − − ?− − − 0  
2289 FKBP5 8.59 0 1.56 + + + + + + 0 0.75 0.58
64231 MS4A6A 8.57 0 1.43 + + + + + + 0 0.62 0.51
78991 PCYOX1L − 8.57 0 0.67 − − − − − − 0 − 0.64 − 0.59
1846 DUSP4 − 8.51 0 0.70 − − ?− − − 0 − 0.74 − 0.54
7108 TM7SF2 − 8.49 0 0.78 − − ?− − − 0 − 0.71 − 0.57
6405 SEMA3F 8.47 0 1.32 + + + + + + 0 0.6 0.48
9322 TRIP10 8.42 0 1.38 + + + + + + 0 0.69 0.56
10184 LHFPL2 8.4 0 1.32 + + + + + + 0 0.66 0.56
9315 NREP − 8.39 0 0.75 − − − − − − 0   
381 ARF5 − 8.35 0 0.78 − − − − − − 0 − 0.69 − 0.6
84620 ST6GAL2 − 8.32 0 0.75 − − ?− − − 0 − 0.67 − 0.55
56261 GPCPD1 − 8.31 0 0.72 − − ?− − − 0 − 0.69 − 0.53
79930 DOK3 8.3 0 1.27 + + ?+ + + 0 0.6 0.47
3754 KCNF1 − 8.3 0 0.78 − − − − − − 0 − 0.74 − 0.61
4792 NFKBIA 8.28 2.22E-16 1.54 + + ?+ + + 5.22E-12 0.74 0.58
29906 ST8SIA5 − 8.26 2.22E-16 0.79 − − ?− − − 5.22E-12 − 0.63 − 0.49
26471 NUPR1 8.19 2.22E-16 1.66 + + + + + + 5.22E-12 0.71 0.56
1802 DPH2 − 8.15 4.44E-16 0.89 − − ?− − − 1.04E-11 − 0.52
887 CCKBR − 8.13 4.44E-16 0.71 − − − − − − 1.04E-11 − 0.72 − 0.61
26524 LATS2 8.12 4.44E-16 1.57 + + ?+ + + 1.04E-11 0.71 0.57
3017 HIST1H2BD 8.11 4.44E-16 1.46 + + + + + + 1.04E-11  0.5
Table 1.  The top most significant differentially expressed genes in our meta-analysis. $Average fold 
change. *data from Zhang et al. study11. #“+ /− /?” indicates up/down and missing.
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Endothelial Cells in Rheumatoid Arthritis (adjPval = 1.26E-11, ratio = 56/298); LXR/RXR Activation 
(adjPval = 3.16E-11, ratio = 33/121); IL-8 Signalling (adjPval = 2.09E-10, ratio = 40/183) and B Cell 
Receptor Signalling (adjPval = 2.09E-10, ratio = 39/176). In addition, Interleukin (IL-6, and 10), 
Complement, PPAR Signalling, Acute Phase Signalling and Toll-Like Receptor Signalling pathways were 
prominent. In contrast, for 1708 down-regulated DEGs mapped, only three pathways were identified as 
significant: Mitochondrial Dysfunction (adjPval = 2.24E-06, ratio = 37/172); Oxidative Phosphorylation 
(adjPval = 4.26E-04, ratio = 24/110) and Aspartate Degradation II (adjPval = 7.24E-3, ratio = 5/7) (see 
Supplementary Table S6 online). Thus pathways involving TLR signalling, NFKB activation, NOROS, 
iNOS (also known as NOS2), complement and acute phase responses are identified as up-regulated and 
mitochondrial function as down-regulated in AD (Figs 1 and 2 and Supplementary Fig. S2 online). The 
top ten pathways identified by the up-regulated DEGs and the two by down-regulated DEGs are illus-
trated in Fig.  3. Among the significantly perturbed 168 pathways, RELA is involved in 101 pathways, 
NFKB1 in 100, NFKB2 in 88, NFKBIA in 62 and STAT3 in 32. These pro-inflammatory transcriptional 
factors are DEGs and likely to play an important role in AD pathogenesis.
Age is the strongest risk factor for AD; we therefore conducted an IPA pathway analysis on 
a separate ageing dataset (see Methods) to investigate the shared features between AD and age-
ing. IPA identified 90 significant canonical pathways for up- or down-regulated DEGs in ageing 
(Supplementary Table S7 online), 38 of these pathways were shared with pathways in AD. Amongst the 
top up-regulated pathways were EIF2 signalling (adjPval = 1.05E-10, ratio = 41/169), mTOR signalling 
(adjPval = 1.58E-5, ratio = 33/181), Integrin signalling (adjPval = 1.66E-5, ratio = 34/194) and STAT3 
pathway (adjPval = 6.17E-5, ratio = 18/73). Also active were stem cell, semaphorin and Rho pathways. 
The top down-regulated pathways included Oxidative Phosphorylation (1.35E-6, ratio = 28/96) and 
Mitochondrial Dysfunction (adjPval = 1.82E-6 ratio = 37/157). Overall these ageing pathways indicate 
that the inflammatory pathway is activated, mitochondrial function is suppressed, and regenerative func-
tions are activated.
The top two pathways in AD, NOROS and NFKB, were not detected in ageing by IPA. We there-
fore chose to use gene set enrichment analysis (GSEA)18,19 to analyse in the ageing datasets about the 
up-regulated AD DEGs in NOROS and NFKB Signalling pathways, and the down-regulated AD DEGs in 
Mitochondrial Dysfunction (MitoDys) and Oxidative Phosphorylation (OXPHOS) (see Methods). GSEA 
identified a set of up-regulated gene sets in ageing which included the above NOROS and NFKB sets as 
Figure 1. iNOS pathway identified by IPA. The iNOS pathway is identified as one of the significant 
pathways by IPA. It is also part of NOROS, the most significant pathway. Here all the genes were overlaid 
to the DEGs. All the up-regulated DEGs are red while CALM is the solitary down-regulated DEG (green). 
Members of the IK-B family are both up- or down- regulated.
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second and third most significant gene sets (Fig. 4, Supplementary Fig. S4 and Supplementary Table S8 
online). NOROS contains 44 up-regulated AD DEGs, 35 of which were mapped to the ageing dataset and 
found to be enriched in ageing (nominal p-value < 2.2E-16, FDR < 2.2E-16). 32 of these AD DEGs are 
also enriched genes in ageing and include the NFKB complex components, NFKBIA, NFKB1 and RELA; 
the GWAS gene CLU; PPARA; and the TNF receptor superfamily members TNFRSF11B, TNFRSF1A 
and TNFRSF1B. The NFKB set contains 41 up-regulated AD DEGs, 35 of which were mapped to the age-
ing dataset with enrichment (nominal p-value < 2.2E-16, FDR < 2.2E-16). GSEA also identified KEGG 
Oxidative Phosphorylation, Parkinson’s Disease, Huntington’s Disease and Alzheimer’s Disease as the 
top down-regulated gene sets in ageing, followed by the MitoDys and OXPHOS sets. This result further 
implicates inflammation through NF-κ B, iNOS activation and ROS production in both normal ageing 
and AD. In addition, NF-κ B activation has previously been observed in mouse ageing models20 and 
recently revealed by epigenomics study in mice and humans21.
Upstream transcription regulators. The upstream regulator analysis (URA) tool is a novel func-
tion in IPA which can, by analysing linkage to DEGs through coordinated expression, identify potential 
upstream regulators including transcription factors (TFs) and any gene or small molecule that has been 
observed experimentally to affect gene expression22. It has recently been used to robustly identify repres-
sor element 1-silencing transcription factor (REST) as an important regulator in AD and ageing12. For 
the up-regulated DEGs in AD, IPA identified 230 activated potential upstream regulators (Bonferroni 
corrected p-value < 0.05, see Supplementary Table S9 online). The top upstream activated regulator is 
predicted to be LPS, whose target receptor is TLR4. In addition to LPS, multiple other bacterial and 
Figure 2. Oxidative Phosphorylation pathway. Though this pathway was identified by IPA for down-
regulated DEGs, no up-regulated DEGs are overlaid. The genes in green are suppressed in LOAD.
Figure 3. Significant pathways identified by IPA. The top ten significant pathways identified for the up-
regulated DEGs (red bar) and two pathways identified for the down-regulated DEGs (green bar). The blue 
curve shows the ratio between the number of DEGs and the total number of genes in each of these pathways 
(see the entire list of IPA pathways in Supplementary Table S2 online).
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endogenous TLR4 ligands, including debris from necrotic cells, connective tissue, coagulation factors and 
importantly Alzheimer’s amyloid ß peptide (Aß) have been identified23. TLR4, STAT3 and NFKBIA are 
DEGs that are also identified here as important upstream regulators of gene up-regulation. Both STAT3 
and NFKBIA are activated through the adaptor protein MYD88, which is a downstream signalling gene 
for TLRs24 and itself is a DEG. STAT3 has a major role in promoting inflammatory pathways. The mech-
anistic networks for these regulators generated by IPA are demonstrated in Supplementary Fig. S3 online. 
Those upstream regulators include 33 activated TFs, 11 of which are DEGs with nine up-regulated and 
two down-regulated. The differentially expressed TFs include 3 NFKB components. Other upstream TFs 
that are DEGs are (a) SMAD4, which is downstream of the growth factor TGFB, and is a major determi-
nant of the pathway Diseases and Biofunctions, Connective Tissue Disorders; (b) IRF1 and IRF7, which 
both regulate the transcription of interferon genes and are linked to TLR signalling; (c) CEBPB, which is 
important in the regulation of genes such as interferons that are involved in immune and inflammatory 
responses, acute-phase and cytokine genes, as well as connective tissue genes. Together these observa-
tions re-emphasise the importance of inflammatory and connective tissue responses in AD.
Among the down-regulated DEGs, IPA identified the AD-associated TF REST (adjPval = 1.53E-9) as 
an upstream regulator, regulating 27 down-regulated DEGs. RICTOR is identified as another activated 
upstream regulator (adjPval = 4.69E-3), and its activation is predicted to regulate 36 down-regulated 
DEGs including multiple mitochondrial genes (see Supplementary Tables S9 and S10 online).
We applied URA to ageing as well. Relevant upstream regulators are shown in Supplementary 
Table S11 online. REST (adjPval = 2.78E-3) is identified as an upstream regulator in ageing as pre-
viously described12 and regulates 24 targets. RICTOR is also detected as another upstream regulator 
(adjPval = 6.35E-6) and regulates 46 targets in ageing.
Protein -protein interaction (PPI) networks. To further elucidate the interactions of the top DEGs 
and the GWAS findings we performed human PPI network analysis (see Methods). We constructed a 
subnetwork by mapping the top 30 DEGs to the PPI network (16 DEGs mapped) and extracted their 
first neighbour nodes (FNN) from the PPI network. This subnetwork contains 175 nodes and 998 edges 
including three GWAS discovered genes: CLU, CR1 and INPP5D (Supplementary Fig. S5 online). The 
two top hubs were NFKBIA and CLU (see Supplementary Table S12 online). NFKBIA is connected to 64 
genes in this subnetwork, including 13 up-regulated DEGs and 10 down-regulated DEGs. These include 
Figure 4. Gene set enrichment analysis (GSEA) for NOROS. GSEA confirms that the NOROS gene set 
containing up-regulated LOAD DEGs is enriched in old people. Microarray data for ageing (GSE53890) 
were analysed using GSEA software to identify significant gene sets (see Methods). The enrichment plot on 
the left shows the distribution of genes in the set that are correlated with the old or young phenotype. The 
heatmap on the right shows where gene expression is relatively high (red) or low (blue) for each gene in the 
indicated sample.
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the NFKB complex up-regulated DEGs RELA, NFKB1, NFKB2 and IKBKE; the down-regulated NFKB 
complex gene NFKBIE; and unperturbed genes CHUK, EIF2K2, IKBKAP, RELB, REL and NFKBIB. CLU 
links to 32 genes including five DEGs: C1QA, C1QC, QDPR, SERTAD3 and SAFB2. C1QA is linked to 
the complement component GWAS discovered gene CR1, which is not a DEG, and other complement 
DEGs C1QB, C1R and C1S (Fig. 5, a subnetwork of Supplementary Fig. S5). Although the function of 
CLU is not known, the linkages identified suggest a key role in innate immune responses through com-
plement activation. Thus the PPI overwhelmingly identifies the importance of NFKB in AD.
We were able to map 14 of the 23 AD GWAS findings to the human PPI network. MS4A6A is the 
only DEG amongst these that is not included. The resulting FNN subnetwork contained 332 nodes and 
7692 edges (Supplementary Fig. S6 online). There was an average of 23 neighbours per node, which was 
much higher than that of the whole human PPI network (OR = 5.22, p-value < 2.2E-16, Fisher-test). This 
subnetwork included 78 DEGs with enrichment (OR = 1.44, p-value = 8.30E-3), such as DOK3, C1QA, 
C1QC, GFAP, SYK, STAT3, SNCA and TYROBP. APOE is the top hub (124 first neighbours) and links 
to 18 DEGs; 10 of these are up-regulated and implicated in inflammation (HP, ITGB5, SERPING1, CFB, 
CFH), lipid metabolism (CHKB, PLTP, DGKG), cytoskeleton (GFAP) or gene expression (NCOA3); 
eight are down-regulated and implicated in the cytoskeleton (TLN2, KRT5, MAPT, NEFM) endocytosis 
and lipid metabolism (VLDLR, EXOC6, TTPAL) or DNA repair (DDB1). Of these, PLTP was reported 
to reduce phosphorylation of tau (MAPT) in human neuronal cells25, and is activated through the top 
pathway, LXR/RXR Activation. Phospholipids have also been described to be important biomarkers 
of pre-symptomatic AD. PTKB2 is the second top hub linking directly other 55 genes including 13 
up-regulated and three down-regulated DEGs. ApoE4 and PTK2B have been previously linked mecha-
nistically to Aß production by ApoE4 stimulated neuroblastoma cells9. PTK2B physically interacts with 
the receptor tyrosine kinase EPHA1, encoded by another AD gene; both of these genes are implicated in 
vascular inflammation and blood flow. TYROBP and TREM2 are first neighbours in the network. Other 
hubs are shown in Supplementary Table S13 online.
Discussion
In this study, we used an approach to meta-analysis in which, by focusing on the prefrontal cortex, all 
the genes across different studies are included. Previous integrative AD studies either pooled the raw 
Figure 5. Protein-protein interaction (PPI) network for NFKBIA, C1QA and CLU . The red nodes 
indicate the up-regulated DEGs, while green nodes indicate the down-regulated DEGs. Grey and blue 
nodes are not DEGs. All the DEGs are linked by blue lines. NFKBIA, C1QA and CLU are among the top 
30 DEGs (see Table 1). Both CLU and CR1 are GWAS genes (see Supplementary Table S2 online). This is a 
subnetwork of the PPI network for the top 30 DEGs (see Supplementary Fig. S5 online).
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data9 or combine the results from different brain regions26. Most microarray meta-analysis only use genes 
reported across all the studies (the ‘common genes’)26, so the more the studies that are included in a 
meta-analysis, the smaller the number of common genes. In our study, to have ignored the many genes 
that are not common (19692 out of 23530) would have created many false negatives. We would have not 
only missed important GWAS genes (CD2AP, INPP5D, TREM2, CLU, ABCA7) but also other genes with 
known functions in AD such as BDNF27. Q-Q plot demonstrates that the normality of the combined 
metaZscore is improved by including non-common genes. In this respect, our alternate p-value based 
method performed similarly to our main effect-size based approach (Supplementary Fig. S7 online).
Overwhelmingly our results bring together enhanced TLR4 signalling and activation of NFKB tran-
scription with up-regulation of NO and ROS production and complement as key mechanisms of neu-
roinflammation in AD (Figs 1 and 6, Supplementary Fig. S3 online). Upstream regulator analysis by IPA 
identifies the bacterial product LPS as the top upstream regulator. While low levels of LPS are found in 
human blood, multiple other pathogen-derived and endogenous ligands for TLR4 have been identified, 
and these include debris from necrotic cells, connective tissue, coagulation factors and importantly AD 
ß-amyloid peptide23,28. Amongst the DEGs recovered in our IPA and PPI analysis, NFKB is highlighted 
by our study as a key pro-inflammatory TF in AD. NFKB activates NOS2 in microglia29,30, and NOROS 
activation is identified as the top pathway by IPA. LPS is also a key regulator of the production of ROS 
by NADPH oxidase as identified in the NOROS pathway. The combined activation of NO and ROS 
production could stimulate creation of highly injurious nitrosative stress, which is particularly damaging 
to mitochondria31. Astrocytes and microglia are also the likely source of complement32. We also find evi-
dence for activation of multiple other inflammatory and connective tissue-disorder pathways mediated 
through pro-inflammatory TF genes such as STAT3, IRF1 and IRF7, CEBPB and SMAD4.
A gene set of up-regulated DEGs in NOROS showed highly significant association with normal ageing. 
Previously, NFKB, REST and complement C1Q have been associated with normal ageing, but to the best 
of our knowledge TLR4 signalling and NOROS activation have not12,15,20. Although we did not identify 
NOROS and NFKB pathways in ageing directly by IPA, GSEA reveals that gene sets with up-regulated 
AD DEGs in NOROS and NFKB were highly activated in ageing samples (Fig. 4 and Supplementary Fig. 
S4 online). These results suggest that AD might develop through direct corruption of the normal ageing 
process, as well as through independent pathways of amyliod plaque and NFT production triggered by 
ageing. The activation of stem cells, semaphoring and Rho pathways suggest that regenerative functions 
are activated. The importance of such pathways in normal ageing is highlighted by recent parabiotic 
studies comparing young and old mice33,34.
Both DOK3 and TYROBP are identified as up-regulated DEGs. DOK3 and TYROBP are adaptor 
proteins that modulate the signalling of LPS through TLR413. TYROBP is also a signalling adaptor for 
TREM2, which is an up-regulated DEG and also a risk gene discovered by GWAS14. TYROBP, DOK3 
and TREM2 inhibit LPS signalling through TLR4 in macrophages and prevent inflammation35. We find 
that DOK3 also interacts with the INPP5D, which is encoded by an AD risk gene, thereby interfering 
with phosphatidylinositol metabolism. INPP5D also functions as a negative regulator of inflammatory 
cell proliferation and survival36. Together these results strongly implicate the TLR4 signalling pathway 
in symptomatic AD.
With regard to the GWAS discovered genes we show that APOE, the major genetic determinant of 
LOAD, and PTKB2 are the two top hubs in our PPI analysis. While its function is not known, MS4A6A 
is co-ordinately expressed with TYROBP and complement genes, and is expressed in monocytes and 
Figure 6. Regulation pathway of LPS/TLR4. The diagram shows the activation of the TLR4 signalling 
pathway by LPS or by surrogate ligands such as Aß, and activation of STAT3 and NFKB through the 
adaptor MYD88. NFKB and STAT3 activate NOS2 (iNOS), acute phase responses, complement and other 
inflammatory processes. The DOK3, TYROBP, TREM2 complex regulates the interaction between LPS and 
TLR4 and is in turn modulated by У-secretase.
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glandular cells (http://www.biogps.org). This suggests a role in the key up-regulated processes we describe, 
namely TLR4 signalling and complement activation in microglia, and perhaps secretion (Fig. 6). While 
the newly discovered AD risk gene TRIP4 is not a DEG in our study, it forms a PPI with six DEGs: 
NFKB1, RELA, CREBBP, ESR1, NCOA1 and TBP. TRIP4 is highly expressed in the immune system and 
is a target of NFKB16.
We discovered a down-regulated series of most highly differentially expressed genes (DEGs), 
NEUROD6, ZCCHC17, PPEF1, MANBAL, and BDNF, which were strongly correlated with neuropathol-
ogy. NEUROD6 encodes a TF and its expression is maintained in differentiated neurons in the adult 
brain, where high levels of its mRNA are sustained in mature pyramidal neurones of the hippocampus, 
cerebellum and cortical regions associated with learning and memory37–39. NEUROD6 links neuronal 
differentiation to survival and endows the cells with increased oxidative stress tolerance via a network of 
molecular chaperones, organisation of the cytoskeleton, and enhanced mitochondrial biogenesis and bio-
energetics. In mouse, expression of NeuroD6 parallels neuronal differentiation, and directs post mitotic 
cell fate40. A further recent report has inferred that NEUROD6 might be a possible down-regulated bio-
marker for AD through a comparison of two publicly accessible RNA sequencing (RNAseq) datasets and 
three microarray datasets41. ZCCHC17 (zinc finger, CCHC domain-containing 17), is a novel TF. The 
CCHC-type zinc finger motif is involved in DNA and RNA binding, and can mediate protein-protein 
interactions. The function of ZCCHC17 is not known, but it is highly expressed in the brain and in mye-
loid cells. Another family member, ZCCHC9, can suppress the transcription activity of NFKB, and may 
play a role in the MAPK signalling pathway42. PPEF1 is a serine/threonine-protein phosphatase with two 
calcium-binding EF-hands and is suggested to be involved in sensory neuron function and development, 
sharing high sequence similarity with the Drosophila retinal degeneration C (rdgC) gene. MANBAL 
is a mannosidase, beta A, lysosomal-like gene. Importantly the targeting of proteins to lysosomes and 
endosomes through the mannose-6-phosphate receptor facilitates the conversion of APP to Aß by the 
APP processing enzyme BACE1 through co-localisation with APP in early endosomes43. BDNF is a 
well-characterised secreted neurotrophic factor, which supports neuronal survival and the growth of 
new neurones and synapses44. It is active in the hippocampus, cerebral cortex, and basal forebrain—all 
areas vital to learning, memory, and higher thinking. BDNF levels are reduced in the brain tissues of 
people with AD, where hippocampus damage lowers the levels of BDNF. BDNF also has a protective 
role against ß-amyloid toxicity. BDNF gene transcription is regulated by calcium, like NEUROD6 and 
calcium metabolism is well known to be aberrant in AD. However, the roles of these top DEGs in AD 
are still not clear.
We see dramatic evidence for mitochondrial dysfunction, notably oxidative phosphorylation, in our 
AD dataset as well as in ageing. Upstream regulator analysis in IPA identifies RICTOR as a potential 
regulator of the transcription of multiple genes involved in oxidative phosphorylation and other mito-
chondrial functions. RICTOR is part of the mTOR pathway, mTORC2 complex, and potentially inhibits 
nuclear mitochondrial expression through down-regulation of the transcript factor YY1 and transcrip-
tional co-repressor PGC1A45,46, however, YY1 and PGC1A are not DEGs in AD.
A limitation of our study is that we chose to analyse data from the frontal lobe region in order to 
maximise the number of directly comparable samples. Unlike the hippocampus and entorhinal cortex 
that are affected early in AD, as seen in early Braak stage, the frontal lobes are affected later, when disease 
pathology becomes more pervasive. Nonetheless, similarities in gene expression in AD patients in the 
frontal lobe region and other brain regions are well documented47. In future meta-analysis we propose 
to integrate data from all brain regions to find globally important genes and pathways.
In conclusion, our meta-analysis strategy maximises the use of AD database information and has 
correlated DEGs with cerebral pathology. Analysis of the results identifies some well-recognised genes 
and some new genes in AD. In particular we highlight the possible role TLR4 in AD through (a) its 
up-regulation, (b) its modulation by TYROBP, DOK3, TREM2 and INPP5D, and (c) its signalling 
through NFKB leading to microglial NO and complement activation. We confirmed REST as a major 
predicted upstream regulator in AD and ageing through perturbation of Wnt signalling12. We discovered 
new AD genes, of which the most important are perhaps the strongly down-regulated DEGs NEUROD6, 
ZCCHC17, PPEF1 and MANBAL. We also present evidence for links between AD and phosphatidy-
linositol and calcium signalling as well as through the previously known top LOAD genes APOE and 
PTK2B, which are potentially linked to blood brain barrier dysfunction and blood flow. These insights 
suggest several new avenues for mechanistic research into AD and potential drug targets.
Materials and Methods
Our approach to integrating public gene expression data generated by different microarray platforms was 
as follows. First, we calculated study-specific statistics by comparing mRNA expression level between 
LOAD and control post-mortem brain tissues in the frontal cortex region by the limma48 R package. 
We then applied an effect size-based meta-analysis method to calculate the combined effect size, and 
obtained the relevant statistical p-value by assuming a normal distribution with Bonferroni correction 
for multiple testing to identify combined-study DEGs. Thereafter, we performed pathway and upstream 
analysis on these DEGs, and constructed networks based on known protein-protein interactions to reveal 
the relationships at the protein level and thereby identify pathways involving multiple DEGs.
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Data collection and pre-processing. We searched arrayExpress and GEO for all LOAD-related 
mRNA expression studies that included human post mortem brain tissues from super frontal gyrus 
(SFG) or prefrontal cortex (PFC), both of which are part of the frontal lobe. We found and downloaded 
six profile datasets with GEO accession numbers GSE5281, GSE48350, GSE36980, GSE15222, GSE44770 
and GSE33000. We also downloaded the GSE53890 human brain ageing dataset for comparison. Please 
see Supplementary Information for details about data processing.
Meta-analysis. The basic theory of meta-analysis of microarray study was described initially by Choi 
et al.49, and has subsequently been modified and widely applied7,50–52. Here we briefly provide the appli-
cation formulas proposed by Marot et al.52, which involve an inverse variance-weighted effect size 
meta-analysis method based on moderated t-statistics calculated by the limma R package48. In a 
case-control study, for a given gene, assume there are n1 replicates in the case group and n2 replicates in 
the control group. The biased effect size d can be estimated by the relevant t-statistic, e.g., d t n= /  and 
the biased variance of effect size is given by the following formula:
var d m
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2= +  and m is the number of degree of freedom which is the sum of the prior degree of 
freedom and the residual degree of freedom for the linear model of a certain gene. This is the total num-
ber of degrees of freedom as calculated by the limma method. The value of C(m) is derived as follows:
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Where Γ can be performed by the gamma function in R, and therefore the unbiased effect size can 
be modified as d′ = C(m)d . There are two steps to estimate the unbiased variance: first substitute d′ into 
Equation (1) to get the modified variance, then multiply the squared value obtained from equation (2), 
i.e., C(m)2, to obtain the estimated unbiased variance var(d′ ) of the unbiased effect size d′ . The weight for 
effect size d′ is given by w = 1/var(d′ ), and the final combined metaZscore can be calculated as follows:
=
∑( ′)
∑ ( )
⁎
metaZscore
w d
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Assuming a normal distribution, the relevant p-value can be calculated (denoted as metaPval) in R 
using metaPval= 2*(1 − pnorm(abs(metaZscore))). If a gene is missing in a particular sample from a 
particular study (null value), then the actual sample size will be used in equation (1) or we impute the 
null values using the impute R package53 first. We use the actual sample size method. If a gene is not 
included in a particular study, then we can either impute its effect size54 or simply ignore its contribu-
tion55 in equation (3). e.g. setting the relevant weight w to zero. We adopt the latter method which is also 
widely applied in GWAS meta-analysis3,6,56,57. If a gene is a singleton, i.e. only present in one study, then 
its Benjamini & Hochberg (BH) adjusted p-value as calculated by the limma would be treated as the final 
metaPval and the relevant metaZscore would be estimated by a standard normal distribution. Marot et 
al.52 also proposed an alternative relatively simple meta-analysis solution, e.g. sample-size weighted 
one-side p-value combination method. This method substitutes w n=  and d′ = φ−1(1 − pval) into 
equation (3), where φ−1(x) is the inverse cumulative distribution function of standard normal distribu-
tion. The effect direction in each study for each gene is recorded. For example, in the final meta-analysis 
the effect “+ + ?− + + ” for a certain gene indicates that this gene was up-regulated (+ ) in the first two 
and last two studies; down-regulated (− ) in the fourth study and missed (?) in the third study. We adjust 
p-values by Bonferroni correction for stringency and conduct Q-Q plot to test the normality. All calcu-
lations were completed in R (http://www.bioconductor.org) and a relevant R package is under develop-
ment by the authors. We note that, existing microarray gene expression meta-analysis R packages, such 
as metaMA52, assume that the data are from the same genes in each individual study and apply fixed 
sample size for all genes in the individual studies, thereby ignoring the effect of missing values. In con-
trast, our approach does not require the same gene dimension for each study, i.e. we work on the com-
bined gene set from all the studies involved in the meta-analysis.
Identification of activated transcriptional regulator and pathway analysis. We used the com-
mercial QIAGEN’s Ingenuity® Pathway Analysis (IPA® , QIAGEN Redwood City, www.qiagen.com/inge-
nuity) software for functional pathway and upstream regulatory analysis (URA) of DEGs identified in 
this study. We used the Benjamini-Hochberg method to adjust canonical pathway p-values, and set 0.01 
as the significant threshold. For URA, we used the Bonferroni method to correct the detection p-value 
and set 0.05 as the significant threshold. Geneset enrichment analysis (GSEA)18,19 is widely applied to 
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determine whether a predefined geneset shows statistically significant difference between two biological 
states among a list of genesets. We applied GSEA to the ageing dataset in order to compare four genesets 
identified from AD meta-analysis (NOROS and NF-kB Signalling pathways, Mitochondrial Dysfunction 
(MitoDys) and Oxidative Phosphorylation (OXPHOS) and other KEGG (Kyoto Encyclopedia of Genes 
and Genomes) pathways downloaded from MiSigDB (http://www.broadinstitute.org/gsea/msigdb/). We 
used phenotype permutation for 1000 times, and chose the weighted signal to noise statistical approach 
to rank genes and complete the GSEA analysis.
Protein-protein interaction network analysis. In order to reveal the interactive relationships 
among the DEGs at the protein level, we first downloaded the human protein-protein interaction net-
work (PPIN) from the Human Protein Reference Database (HPRD, release 9, www.hprd.org), and created 
a whole human PPIN which contained 8,603 unique protein entries (nodes) and 44,376 unique undi-
rected interactions (edges). This was visualized using Cytoscape 3.058. We then mapped both the DEGs 
identified by our meta-analysis and known loci of AD risk to this PPIN to build relevant subnetworks.
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